MIRM

Earnings

Mirum Raises Sales Outlook To $715 Million-$720 Million, Sees Revenue Adding $10 Million-$15 Million A Quarter Through 2027

Executives on the earnings call named adult PFIC as the biggest driver of the raised outlook and said newly launched Atebrios should be adopted faster than Livmarli.

SEC Filings

Mirum Paid $62.0 Million In Cash To Retire $20.0 Million Of Convertible Notes

The September buyback left $59.0 million of 2029 notes convertible through year-end, while equity fell to a $54.2 million deficit.

Earnings

Mirum Raises 2026 Sales Guidance To $715 Million-$720 Million As Quarterly Loss Hits $40.8 Million

The rare disease drugmaker posted a third-quarter loss as R&D spending climbed, even as net product sales grew to $185.7 million.

SEC Filings

No Treated Child Developed New Bone Lesions In Mirum's FOP Trial, While One On Placebo Did

Mirum plans a label-expansion filing in the first half of 2027 after its drug cut abnormal bone growth in children aged 6 to under 12.

SEC Filings

Mirum's Livmarli Cuts Itch Versus Placebo In 52-Patient Phase 3 Trial, Sets 2027 Filing Plan

The drug met the trial's main goal and all five secondary measures, and Mirum plans a U.S. supplemental application in the first half of 2027.

SEC Filings

FDA Clears Mirum's Atebrioz For Rare Bone-Hardening Disease, And A Separate Hepatitis Delta Trial Hits Its Primary Goal

The FDA approved Atebrioz on Friday; the same day, Mirum's late-stage AZURE-1 hepatitis delta study met its primary endpoint at week 24.